← Browse by Condition
Medical Condition
spinal tumor
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT06161974 Phase 2
Recruiting
Study of Olutasidenib and Temozolomide in HGG
Enrollment
60 pts
Location
United States, Austr...
Sponsor
Rigel Pharmaceuticals
NCT06587022
Recruiting
Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors
Enrollment
500 pts
Location
China
Sponsor
Peking University Third Hospit...